inVentiv Health’s Campbell Alliance Launches Consulting Services in Japan for Clients Seeking Commercial Expertise and Support in Asia
March 24, 2014
Pawel Komender Appointed Regional General Manager to Lead the New Tokyo Office
BURLINGTON, MA. and TOKYO, JAPAN – Campbell Alliance, an inVentiv Health company and industry leader in biopharmaceutical consulting, today announced the launch of its consulting business in Japan and the opening of its Tokyo office. Campbell’s presence in Tokyo complements a dozen other locations in North America and Europe where inVentiv has on-the-ground consulting services.
The opening of the consulting office allows inVentiv to act as a strategic partner for any biopharmaceutical company conducting business in Asia. The Japanese office will offer all the services and expertise clients count on from inVentiv, including:
- Market Assessment and Opportunity Identification
- Pricing and Market Access
- Market Entry and Go-to-Market Strategy
- Product Launch
- Commercial Excellence
- In- and Out-Licensing
The Campbell Alliance office in Asia will operate as inVentiv Health Consulting.
“inVentiv Health Consulting will provide in–market capabilities and presence for U.S.-based companies looking to better understand the Japanese market,” said Darius Naigamwalla, President of Campbell Alliance “For Japanese clients wanting Japan-based support, we will provide local presence and accessibility. The office also will round out our industry-leading global Pricing and Market Access Capabilities, as well as offer seamless delivery of solutions to support all aspects of product development and commercialization. Our focus is on helping clients solve intricate problems, optimize emerging opportunities and succeed in an evolving marketplace."
In leading the new office, Pawel Komender will leverage nearly 20 years of professional experience in Japan and a track record of assignments in the Asia Pacific region. Prior to joining Campbell Alliance, Mr. Komender worked with Accenture Japan and Simon-Kucher & Partners. He is fluent in Japanese, English, German, and Polish.
“Pawel’s background in strategic consulting and his deep functional knowledge, as well as his experience working in the Japanese market, make him the ideal person to lead our consulting business and our anticipated growth in Japan,” Naigamwalla said.
About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health and an industry leader in biopharmaceutical consulting. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into three Centers of Excellence—Commercial, Medical, and Corporate Development—each of which offers a range of services to a critical area of the pharmaceutical and biotechnology industries. Each of our Centers of Excellence is a dedicated consulting team whose members are highly specialized and offer deep expertise in their chosen areas. From its 13 office locations, the firm serves clients throughout North America, Europe, and Asia. For more information on Campbell Alliance, please visit www.campbellalliance.com.
About inVentiv Health
inVentiv Health, Inc., is a life science knowledge and services company purpose-built for the new health care marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client’s development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.